Literature DB >> 225007

Cell kinetic analyses of human malignant brain tumors (gliomas).

T Hoshino, C B Wilson.   

Abstract

Administration of 3H-thymidine, either with or without mitostatic agents, to 24 patients with various gliomas revealed 1) in viable areas a labeling index (LI) for glioblastomas equal to 5-15%, 2) an LI of 1% or less in well-differentiated gliomas, and 3) the LI of anaplastic astrocytomas was intermediate and reflected the extent of anaplasia. Growth fraction was 0.14-0.44 in malignant gliomas (average 0.31 +/- 0.10), and cell cycle time obtained by means of stathmokinetic analysis was 75.6 +/- 45.7 hr. With few exceptions, the patients whose tumors showed an LI of 5% or more died within 1 year after the onset of disease, and no patients whose tumors at biopsy had an LI of over 5% survived more than 6 months. In contrast, there was a far better prognosis for patients whose tumors demonstrated an LI of less than 1%.

Entities:  

Mesh:

Year:  1979        PMID: 225007     DOI: 10.1002/1097-0142(197909)44:3<956::aid-cncr2820440325>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  47 in total

1.  Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma.

Authors:  D Fulton; R Urtasun; P Forsyth
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

2.  Correlation between nucleolar organizer region score and bromodeoxyuridine labeling index in C6 glioma cell line.

Authors:  A Hara; S Niikawa; H Hirayama; N Sakai; H Yamada; T Ohno; T Tanaka; H Mori
Journal:  J Neurooncol       Date:  1991-10       Impact factor: 4.130

3.  Nucleolar organizer region score and Ki-67 labelling index in high-grade gliomas and metastatic brain tumours.

Authors:  A Hara; H Hirayama; N Sakai; H Yamada; T Tanaka; H Mori
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

4.  Variability in the proliferative potential of human gliomas.

Authors:  T Hoshino; T Nagashima; K G Cho; R L Davis; J Donegan; M Slusarz; C B Wilson
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

Review 5.  Invasiveness of primary brain tumors.

Authors:  O D Laerum; R Bjerkvig; S K Steinsvåg; L de Ridder
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

6.  Fetal origin of the medulloblastoma: evidence from growth analysis of two cases.

Authors:  K Hirakawa; K Suzuki; S Ueda; J Handa
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

7.  Effects of intralesional injection of cisplatin dissolved in urografin and lipiodol on Ehrlich ascites tumor and normal tissues of CD-1 mice.

Authors:  J E Landrito; K Yoshiga; K Sakurai; K Takada
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  New treatment protocol by intra-operative radiation therapy for metastatic brain tumours.

Authors:  O Nakamura; M Matsutani; N Shitara; K Okamoto; M Kaneko; H Nakamura; A Asai; K Ueki; T Shimizu; Y Tanaka
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

9.  Rapid estimation of the proliferating index of brain tumours.

Authors:  A Detta; E Hitchcock
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

10.  Proliferating cell nuclear antigen immunoreactivity in human central nervous system neoplasms.

Authors:  E Karamitopoulou; E Perentes; M Melachrinou; T Maraziotis
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.